KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Dividends Paid - Common (2016 - 2025)

Historic Dividends Paid - Common for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $15.1 million.

  • West Pharmaceutical Services' Dividends Paid - Common rose 413.79% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.7 million, marking a year-over-year increase of 358.36%. This contributed to the annual value of $59.1 million for FY2024, which is 368.42% up from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Dividends Paid - Common is $15.1 million, which was up 413.79% from $15.1 million recorded in Q2 2025.
  • West Pharmaceutical Services' Dividends Paid - Common's 5-year high stood at $15.3 million during Q4 2024, with a 5-year trough of $12.6 million in Q1 2021.
  • Its 5-year average for Dividends Paid - Common is $14.0 million, with a median of $14.1 million in 2022.
  • In the last 5 years, West Pharmaceutical Services' Dividends Paid - Common surged by 763.36% in 2023 and then skyrocketed by 337.84% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Dividends Paid - Common (Quarter) stood at $13.3 million in 2021, then grew by 6.02% to $14.1 million in 2022, then grew by 4.96% to $14.8 million in 2023, then increased by 3.38% to $15.3 million in 2024, then dropped by 1.31% to $15.1 million in 2025.
  • Its Dividends Paid - Common was $15.1 million in Q3 2025, compared to $15.1 million in Q2 2025 and $15.2 million in Q1 2025.